Company: MYGN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0000899923-25-000086
Chunk: 120

Company: MYRIAD GENETICS INC
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 2
Chunk 120
---
 laboratory reagents and supplies. 

Research and Development Expense

Six months ended June 30,(in millions)20252024Change% ChangeResearch and development expense$53.1 $52.7 $0.4 1 %Research and development expense as a % of total revenue13.0 %12.7 % 

Research and development expense for the six months ended June 30, 2025 were relatively consistent with the expenses incurred in the same period of the prior year, reflecting stable operating activities across the business.

Sales and Marketing Expense

Six months ended June 30,(in millions)20252024Change% ChangeSales and marketing expense$141.1 142.2 $(1.1)(1)%Sales and marketing expense as a % of total revenue34.5 %34.4 %

Sales and marketing expense for the six months ended June 30, 2025 were relatively consistent with the expenses incurred in the same period of the prior year, reflecting stable operating activities across the business. 

General and Administrative Expense

Six months ended June 30,(in millions)20252024Change% ChangeGeneral and administrative expense$133.3 142.7 $(9.4)(7)%General and administrative expense as a % of total revenue32.6 %34.5 %

General and administrative expense decreased by $9.4 million for the six months ended June 30, 2025 compared to the prior year primarily due to a decrease of $4.1 million in consulting fees, a $3.4 million decrease in amortization for previously impaired intangible assets, and a $3.2 million decrease in compensation and benefits.

26

Goodwill and Long-lived Asset Impairment Charges

Six months ended June 30,(in millions)20252024Change% ChangeGoodwill and long-lived asset impairment charges$316.7 $11.6 $305.1 2630 %Goodwill and long-lived asset impairment charges as a % of total revenue77.4 %2.8 %

Goodwill and long-lived asset impairment charges in the six months ended June 30, 2025 included goodwill impairment charges of $234.7 million and intangible asset impairment charges of $82.0 million related to our Women's Health and Pharmacogenomics reporting units. For additional information regarding the testing and analysis performed, refer to "Critical Accounting Estimates" in this Item 2, "Management's Discussion and Analysis